Biosimilars

Biosimilars are biological products that are highly similar to and have no clinically meaningful differences from an existing FDA-approved reference product. They are developed to have the same mechanism of action, route of administration, dosage form, and strength as the reference product. Biosimilars are not generic drugs, as they are derived from living organisms and their production involves complex manufacturing processes. The introduction of biosimilars in the market can increase competition, potentially leading to reduced costs and increased access to biological therapies for patients. Despite their similarities, biosimilars and their reference products may have minor differences in inactive components.

    Related Conference of Biosimilars

    July 27-28, 2026

    19th World Drug Delivery Summit

    Paris, France
    July 27-28, 2026

    39th World Congress on Pharmacology

    Rome, Italy
    September 14-15, 2026

    6th International Conference on Pharmaceutical Chemistry

    Paris, France
    September 24-25, 2026

    6th World Congress on Rare Diseases & Orphan Drugs

    Paris, France
    November 26-27, 2026

    5th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland
    November 26-27, 2026

    5th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    January 26-27, 2027

    22nd Annual Meet on Pharmaceutical Sciences

    Paris, France
    April 27-28, 2027

    10th European Biopharma Congress

    Paris, France

    Biosimilars Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in